NeuroPace Q1 Sales Up 19.5%, Guidance Raised to 21–23% with $20 Price Target
NeuroPace reported a Q1 adjusted loss of $0.13 per share on $22.1 million revenue, driven by a 19.5% increase in RNS System sales to $21.7 million. The company raised its full-year 2026 RNS System sales growth target to 21–23% and saw its price target lifted to $20.
1. Q1 2026 Financial Results
NeuroPace reported an adjusted loss of $0.13 per share in the first quarter and generated $22.1 million in revenue, with RNS System sales totaling $21.7 million, up 19.5% year-over-year.
2. Raised 2026 RNS System Sales Guidance
NeuroPace raised its full-year 2026 RNS System sales growth forecast to a range of 21% to 23%, reflecting management’s confidence in continued product demand and market expansion.
3. Improved Operational Efficiency
The company narrowed its adjusted EBITDA loss to $3.3 million from $4.1 million in the prior-year quarter, highlighting improvements in operational efficiency and cost management.
4. Analyst Rating and Price Target
Following the strong performance, analysts maintained a Buy rating on NeuroPace and increased the price target to $20, underscoring market optimism around the company’s growth prospects.